Skip to main content

Table 1 Model input parameters

From: Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece

Parameters Agomelatine Venlafaxine Fluoxetine Sertraline Escitalopram
Dose 25 mg 75 mg 20 mg 50 mg 20 mg
Percentage of patients receiving double dose 22.1% 11.8% 23.0% 24.5% 0.0%
Remission 0.323 [2022] 0.323* 0.284 [22] 0.289 [21] 0.323*
Recurrence 20% [25] 20% [25] 20% [25] 20% [25] 20% [25]
Suicide risk 20.35 [26] 20.35 [26] 20.35 [26] 20.35 [26] 20.35 [26]
Discontinuation 0.117 [2023] 0.216 [20] 0.171 [22] 0.189 [21] 0.144 [23]
Discontinuation symptoms 0.00 [27] 0.20 [27] 0.00 0.00 0.07
Relapse Survival function [28] Survival function [28] RR:0.513§ RR:0.633§ RR:0.531§
Constipation 0.027 [2023] 0.042 [20] 0.011 [22] 0.006 [21] 0.006 [23]
Dyspepsia 0.020 [2023] 0.024 [20] 0.008 [22] 0.013 [21] 0.025 [23]
Diarrhoea 0.040 [2023] 0.018 [20] 0.027 [22] 0.057 [21] 0.069 [23]
Nausea 0.066 [2023] 0.226 [20] 0.114 [22] 0.044 [21] 0.138 [23]
Somnolence 0.035 [2023] 0.048 [20] 0.034 [22] 0.013 [21] 0.038 [23]
Headache 0.111 [2023] 0.119 [20] 0.114 [22] 0.101 [21] 0.144 [23]
Sexual Dysfunction 0.005 [2023] 0.018 [29] 0.004 [22] 0.019 [21] 0.013 [23]
Sleep Disorder 0.007 [2023] 0.024 [20] 0.019 [22] 0.019 [21] 0.025 [23]
  1. *assumed to be equal to agomelatine due to lack of relevant data.
  2. §Meta-analysis vs. Placebo.